(IMPAACT 1026S) Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy

In order for our site to display correctly you will need a newer version of your web browser.

Currently we test and support the following browsers:

FireFox version 3.0 and above (Windows and Mac)
Safari version 5.0 and above (Windows and Mac)
Internet Explorer version 7.0 and above (Windows)

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Research

HIV Studies

Supportive HIV Studies

Protocol

AT1026 (P1026): (IMPAACT 1026S) Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy

Diseases

Infectious Diseases : HIV Infection

Description

Studies have shown that women and men differ in how their bodies metabolize certain drugs. Pregnancy may have an additional effect on drug metabolism for women. Pregnant women experience unique physiological changes that may result in clinically significant changes in drug pharmacokinetics (the way the body uses the drug) and pharmacodynamics (how the drug acts on the body).

This study will evaluate the pharmacokinetics and pharmacodynamics of currently prescribed antiretroviral drugs and interacting combinations of these drugs in pregnant HIV-infected women.

Objectives

Evaluate the pharmacokinetics and pharmacodynamics of selected antiretroviral drugs currently used in therapy of pregnant HIV-infected women.
Compare antiretroviral drug levels in blood from the mother and her baby at time of birth.

Eligibility

HIV-infected pregnant women greater than or equal to 26 weeks gestation who are enrolled on IMPAACT P1025.
Receiving adult dose of antiretroviral drug, with the plan to continue for six weeks after delivery.
Not taking any medication known to interfere with absorption, metabolism or clearance of the antiretroviral drug being evaluated.
Not carrying multiple fetuses.

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).

Contact

Katherine Knapp, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-866-2ST-JUDE (1-866-278-5833)
FAX: 901-521-9005

Referring or consulting physicians only: protocolinfo@stjude.org
For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Print Email This Article